Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's patent rights in nerve-stimulation technology.

Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy Axonics, which was announced in January.

A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run afoul of three patents held by the company’s main rival, Medt | The case is one of several intellectual property disputes between the medtech giant and Axonics—which is currently waiting to become a subsidiary of Boston Scientific.

Axonics Inc. (NASDAQ:AXNX) rose 1.5% in after hours trading after a jury voted in is favor in a patent dispute with Medtronic (MDT). Medtronic (MDT) was seeking $150 million in a patent dispute with Axonics (AXNX),

Axonics (Nasdaq:AXNX) announced today that a jury unanimously ruled in its favor in a patent spat with (NYSE: MDT).